Aptivus (Tipranavir)

What Is Aptivus and What Is It Used For?

Aptivus (tipranavir) is an antiretroviral medication belonging to the HIV protease inhibitor class. It is used in combination with low-dose ritonavir and other HIV medications to treat HIV-1 infection in treatment-experienced patients whose virus has developed resistance to multiple other protease inhibitors.

Tipranavir is a non-peptidic protease inhibitor, meaning its chemical structure differs from older protease inhibitors like lopinavir, atazanavir, and saquinavir. This unique structural profile allows tipranavir to retain activity against many HIV strains that have developed resistance to other drugs in the same class. The HIV protease enzyme is essential for the virus to replicate: it cleaves viral polyprotein precursors into functional proteins needed to assemble new virus particles. By blocking this enzyme, tipranavir prevents the formation of mature, infectious virions.

Aptivus must always be taken together with a low dose of ritonavir, which acts as a pharmacokinetic booster. Without ritonavir, tipranavir is rapidly metabolized by the liver enzyme CYP3A4, resulting in plasma concentrations that are far too low to suppress HIV replication effectively. The co-administration of ritonavir inhibits this metabolic pathway and raises tipranavir levels to the therapeutic range. This boosted regimen is a standard approach used with several protease inhibitors in HIV treatment.

Before initiating treatment with Aptivus, your physician will order resistance testing — a blood test that determines which antiretroviral drugs your particular strain of HIV is susceptible or resistant to. Aptivus is considered appropriate when the results confirm that the virus is resistant to multiple other protease inhibitors but remains susceptible to tipranavir. This targeted approach ensures that the medication is used where it can provide the greatest clinical benefit.

Aptivus soft capsules are approved for use in adults and adolescents aged 12 years and older who have a body surface area of at least 1.3 m² or who weigh at least 36 kg. It is not a first-line treatment for newly diagnosed HIV — it is specifically reserved for patients who have previously received antiretroviral therapy and whose treatment options have become limited due to viral resistance.

What Should You Know Before Taking Aptivus?

Before starting Aptivus, your doctor must evaluate your liver function, check for drug interactions, and confirm that your HIV strain is resistant to other protease inhibitors. Several serious medical conditions and concomitant medications are contraindications to Aptivus use.

Contraindications

There are several situations in which Aptivus must not be used. These absolute contraindications exist because the combination of tipranavir with certain conditions or medications poses an unacceptable risk of serious harm.

Do not take Aptivus if you:

• Are allergic to tipranavir or any of the excipients in the capsule formulation
• Have moderate to severe liver disease (Child-Pugh Class B or C) — your doctor will assess liver function with blood tests before starting treatment
• Are currently taking any of the following contraindicated medications:
  • Rifampin (used for tuberculosis) — dramatically reduces tipranavir levels
  • Simvastatin or lovastatin (cholesterol-lowering statins) — risk of rhabdomyolysis
  • Oral midazolam or triazolam (sedatives) — risk of prolonged or excessive sedation
  • Ergot derivatives (for migraine) — risk of ergotism with peripheral vasospasm
  • Pimozide, sertindole, quetiapine, or lurasidone (antipsychotics) — risk of cardiac arrhythmias
  • Cisapride (gastrointestinal agent) — risk of cardiac arrhythmias
  • Astemizole or terfenadine (antihistamines) — risk of cardiac arrhythmias
  • Amiodarone, bepridil, flecainide, propafenone, or quinidine (cardiac drugs)
  • Metoprolol (used for heart failure)
  • Alfuzosin (for benign prostatic hyperplasia) or sildenafil (when used for pulmonary arterial hypertension)
  • Colchicine (when used for gout in patients with renal or hepatic impairment)
• Are taking products containing St. John’s Wort (Hypericum perforatum), as this herbal supplement can significantly reduce tipranavir blood levels and make the medication ineffective

Warnings and Precautions

Even when Aptivus is not contraindicated, there are several important warnings that require careful monitoring during treatment.

Tell your doctor if you have any of the following conditions:

• Hemophilia type A or B: Increased bleeding episodes have been reported in patients with hemophilia taking protease inhibitors
• Diabetes: Blood sugar levels may be affected by antiretroviral therapy, and dose adjustments of antidiabetic medications may be necessary
• Pre-existing liver disease: Even mild liver disease requires more frequent monitoring during Aptivus therapy
• Hepatitis B or C co-infection: Significantly increases the risk of hepatotoxicity

Skin rash: Mild to moderate skin rashes, including urticarial rash, maculopapular rash, and photosensitivity, have been reported in approximately 10% of patients treated with Aptivus. Some patients who developed rash also experienced joint pain, stiffness, throat tightness, or generalized itching. Women taking oral contraceptives may be at higher risk.

Immune reconstitution inflammatory syndrome (IRIS): When HIV treatment is started, the recovering immune system may produce an inflammatory response to previously hidden opportunistic infections such as Mycobacterium avium complex, cytomegalovirus, Pneumocystis jirovecii pneumonia, or tuberculosis. This can cause a temporary worsening of symptoms. Additionally, autoimmune disorders (such as Graves’ disease, polymyositis, or Guillain-Barré syndrome) have been reported months after the start of antiretroviral therapy. Contact your healthcare provider if you notice symptoms of infection or unexplained symptoms such as muscle weakness, tremor, or palpitations.

Cardiac effects: Aptivus in combination with ritonavir may cause changes in heart rhythm and the electrical activity of the heart, which can be detected on an electrocardiogram (ECG). Inform your doctor if you have a history of fainting or abnormal heart rhythms.

Osteonecrosis: Cases of osteonecrosis (death of bone tissue due to loss of blood supply) have been reported in patients on combination antiretroviral therapy. Risk factors include prolonged combination therapy, corticosteroid use, alcohol consumption, severe immunosuppression, and higher body mass index. Symptoms include joint stiffness and pain, particularly in the hip, knee, and shoulder.

Pregnancy and Breastfeeding

The safety of Aptivus during pregnancy has not been definitively established. If you are pregnant, suspect you may be pregnant, or are planning to become pregnant, you should consult your healthcare provider before starting or continuing Aptivus. Your doctor will carefully weigh the potential benefits against the potential risks for both you and the developing fetus.

Breastfeeding is not recommended for women living with HIV, as the virus can be transmitted to the infant through breast milk regardless of whether antiretroviral treatment is being taken. If you are currently breastfeeding or considering doing so, discuss this with your doctor immediately.

Aptivus may reduce the effectiveness of hormonal contraceptives (birth control pills). If you are using oral contraceptives, you should use an additional or alternative method of contraception (such as barrier methods like condoms) while taking Aptivus. Discuss your contraceptive options with your healthcare provider.

Elderly Patients

There is limited clinical experience with tipranavir in patients aged 65 years and older. If you are in this age group, your doctor will exercise particular caution when prescribing Aptivus and will monitor your treatment more closely.

Children

Aptivus soft capsules should not be used in children younger than 12 years of age. For adolescents aged 12 and older, the medication is approved if they have a body surface area of at least 1.3 m² or weigh at least 36 kg.

How Does Aptivus Interact with Other Drugs?

Aptivus has significant interactions with numerous medications because tipranavir and ritonavir affect liver enzymes (particularly CYP3A4) that metabolize many drugs. Some combinations are strictly contraindicated, while others require dose adjustments or enhanced monitoring.

Drug interactions are one of the most critical aspects of Aptivus therapy. Because both tipranavir and its booster ritonavir are potent modulators of the cytochrome P450 enzyme system — particularly CYP3A4 — they can profoundly alter the blood levels of many other medications. Some interactions can make co-administered drugs dangerously elevated, while others can reduce tipranavir levels below therapeutic concentrations. Always provide your physician with a complete list of all medications you are taking, including prescription drugs, over-the-counter medicines, herbal supplements, and vitamins.

Interactions with Other HIV Medications

• Etravirine (NNRTI): Co-administration with Aptivus is not recommended due to unfavorable pharmacokinetic interactions that reduce the effectiveness of both drugs
• Abacavir and zidovudine (NRTIs): Your doctor will only prescribe these NRTIs if other reverse transcriptase inhibitors cannot be used, as tipranavir may reduce their plasma concentrations
• Didanosine (enteric-coated): Must be taken at least 2 hours before or after Aptivus to avoid pharmacokinetic interference
• Emtricitabin: Kidney function should be tested before starting Aptivus if you are also taking emtricitabine
• Rilpivirine: Your doctor will monitor treatment closely if this combination is used
• Other protease inhibitors: Aptivus can cause large reductions in blood levels of other PIs such as amprenavir, atazanavir, lopinavir, and saquinavir. When combined with atazanavir, both tipranavir and ritonavir levels may increase significantly
• Raltegravir and dolutegravir (integrase inhibitors): Dose adjustments may be necessary

Major Interactions with Non-HIV Medications

Interactions Requiring Dose Adjustment or Monitoring

Not Recommended Combinations

The following medications are not recommended for use with Aptivus/ritonavir due to clinically significant interactions:

• Fluticasone (inhaled corticosteroid for asthma) — risk of Cushing syndrome and adrenal suppression
• Atorvastatin — use rosuvastatin or pravastatin at lowest effective dose instead
• Salmeterol (long-acting beta-agonist for asthma/COPD) — risk of serious cardiovascular events
• Bosentan (for pulmonary arterial hypertension) — altered levels of both drugs
• Halofantrine or lumefantrine (antimalarials) — risk of cardiac toxicity
• Tolterodine (for overactive bladder) — risk of increased side effects

What Is the Correct Dosage of Aptivus?

The standard adult and adolescent dose is 500 mg (two 250 mg capsules) of Aptivus taken together with 200 mg (two 100 mg capsules) of ritonavir, twice daily with food. Capsules must be swallowed whole and must not be opened or chewed.

Adults

Aptivus must always be used in combination with other antiretroviral medications as part of a complete treatment regimen. The specific combination will be determined by your physician based on your resistance profile, treatment history, and other individual factors. Never take Aptivus without the ritonavir booster, as the drug will not reach effective blood levels on its own.

Adolescents (12 Years and Older)

The dosage for adolescents who meet the weight or body surface area criteria is the same as for adults. Aptivus soft capsules should not be used in children younger than 12 years.

Elderly Patients

There is limited experience with Aptivus in patients over 65 years of age. No specific dose adjustment is recommended, but your doctor should exercise caution and monitor you more closely, as older patients may have decreased hepatic, renal, or cardiac function and are more likely to be taking concomitant medications.

Missed Dose

Adherence to the prescribed dosing schedule is critical for maintaining viral suppression and preventing the development of drug resistance. If you miss a dose:

• Less than 5 hours late: Take the missed dose as soon as you remember, then continue your regular schedule
• More than 5 hours late: Skip the missed dose entirely and take your next dose at the normally scheduled time
• Never take a double dose to make up for a missed one

Overdose

If you take more than the prescribed amount of Aptivus, contact your healthcare provider or local poison control center immediately. There is limited clinical experience with overdose of tipranavir. Provide your doctor with as much information as possible about the number of capsules taken and when they were consumed. Because tipranavir is highly protein-bound, dialysis is unlikely to significantly remove the drug from the bloodstream.

What Are the Side Effects of Aptivus?

Like all medications, Aptivus can cause side effects. The most common are gastrointestinal symptoms such as diarrhea and nausea. Serious side effects include hepatotoxicity (liver damage) and, rarely, intracranial hemorrhage. Weight gain and metabolic changes (increased blood lipids and blood sugar) may occur with any antiretroviral therapy.

During HIV treatment, weight gain and increased levels of blood lipids and blood sugar may occur. This is partly linked to restored health and lifestyle changes, but in some cases there may also be an association with the antiretroviral medications themselves. Your doctor will order regular blood tests to monitor for these metabolic changes.

It can be difficult to distinguish between side effects caused by Aptivus, those caused by other medications in your regimen, and complications related to the underlying HIV infection itself. For this reason, it is important to report any changes in your health to your healthcare provider.

Bleeding Complications

If you have hemophilia type A or B, you may experience increased bleeding while taking Aptivus or other protease inhibitors. This bleeding can occur in the skin or joints. If you experience increased bleeding episodes, seek medical attention immediately.

Muscle Disorders

Muscle pain, tenderness, and weakness have been reported, particularly when Aptivus or other protease inhibitors are taken together with nucleoside analogue reverse transcriptase inhibitors. In rare cases, these muscle changes have been serious and have involved rhabdomyolysis (breakdown of muscle tissue), which can cause kidney damage.

Side Effects in Children and Adolescents

The most common side effects in children and adolescents are generally similar to those seen in adults. However, vomiting, skin rash, and fever have been observed more frequently in pediatric patients compared to adults.

How Should You Store Aptivus?

Aptivus capsules have specific storage requirements: refrigerate at 2–8°C before opening. Once the bottle is opened, capsules may be stored at room temperature (up to 25°C) for a maximum of 60 days. Always keep medications out of reach of children.

Proper storage of Aptivus is essential to maintain the effectiveness and safety of the medication. The soft gelatin capsules are sensitive to temperature and must be handled according to the following guidelines:

• Before opening: Store in a refrigerator at 2°C to 8°C (36°F to 46°F)
• After opening the bottle: The capsules can be kept at room temperature (up to 25°C / 77°F) and must be used within 60 days
• Write the opening date on the bottle label or outer packaging to track the 60-day expiry
• Do not use after the expiration date printed on the bottle (marked “EXP”), which refers to the last day of the indicated month
• Keep out of sight and reach of children at all times

Do not dispose of medications through household waste or wastewater. Ask your pharmacist about proper disposal methods for medications that are no longer needed. These measures help protect the environment.

What Does Aptivus Contain?

Each Aptivus soft capsule contains 250 mg of the active substance tipranavir. The capsules also contain several excipients and are printed with a black ink marking “TPV 250.”

Active Ingredient

Each capsule contains 250 mg of tipranavir as the active pharmaceutical ingredient.

Inactive Ingredients (Excipients)

The other components of the Aptivus capsule include:

• Capsule contents: Macrogolglycerol ricinoleate, ethanol (alcohol), mono/diglycerides of caprylic/capric acid, propylene glycol, purified water, tromethamine, and propyl gallate
• Capsule shell: Gelatin, red iron oxide, propylene glycol, purified water, special sorbitol-glycerin blend (D-sorbitol, 1,4-sorbitan, mannitol, and glycerin), and titanium dioxide
• Black printing ink: Propylene glycol, black iron oxide, polyvinyl acetate phthalate, macrogol, and ammonium hydroxide

Physical Description

Aptivus soft capsules are pink, oblong soft gelatin capsules imprinted with “TPV 250” in black ink. They are supplied in bottles containing 120 capsules.

Frequently Asked Questions About Aptivus